Nimrodi has served as the executive chairman of Accellix since June 2019.
In order to serve its growing list of customers in the cell and gene therapy market, Accellix has recently launched standardized kits such as the T-Cell and Lymphocyte Subset Assays to provide immediate fixed panels for common markers.
These assays are in addition to the growing number of customized assay kits available to Accellix's global customers.
Nimrodi brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical and biotechnology industries.
In his most recent role, Nir served as the Chief Business officer of Intrexon Corp., a leader in synthetic biology.
Intrexon and its partners are among the pioneering companies in the field of immuno-oncology as well as several other gene therapy programmes.
Prior to Intrexon, Nir held several executive roles at Life Technologies (now part of Thermo Fisher).
While at Life, Nir served as chief executive officer and Board Member of Life Technologies Israel, Head of Protein Technologies, as well as vice president and general manager of Food Safety and Animal Health. Prior to his seven years at Life Technologies, he was the CEO of Proneuron Biotechnologies and Mindsense Biosystems.
Earlier in his career, Nir was a director of Finance for Teva Pharmaceuticals.
Accellix is a biotechnology company dedicated to developing and commercialising the Accellix platform to enable its customers in the field of cell and gene therapy to meet their critical QC requirements as they advance life changing therapies benefiting patients worldwide.
Accellix empowers its customers by migrating their existing cell assays to the Accellix platform.
The Accellix platform is a benchtop cytometer operating and reading capillary cartridges integrated with dry reagents. It provides unmatched reproducibility and ease of use for automated multi-parametric cell analysis.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax